379 related articles for article (PubMed ID: 3043683)
1. Parkinson's disease: recent advances in therapy.
Jankovic J
South Med J; 1988 Aug; 81(8):1021-7. PubMed ID: 3043683
[No Abstract] [Full Text] [Related]
2. What to do when Sinemet fails: Part one.
Klawans HL
Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
[No Abstract] [Full Text] [Related]
3. Medical treatment of Parkinson's disease.
Ahlskog JE
Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
[No Abstract] [Full Text] [Related]
4. Sinemet in Parkinson's disease: efficacy with and without food.
Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB
Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604
[No Abstract] [Full Text] [Related]
5. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
[TBL] [Abstract][Full Text] [Related]
6. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Breck L; Kutt H; McDowell FH
Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
[TBL] [Abstract][Full Text] [Related]
7. Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients.
Klostermann F; Bojarski C; Marzinzik F; Maier A; Schindlbeck KA; Ehlen F
Mov Disord; 2017 Feb; 32(2):300-301. PubMed ID: 27859611
[No Abstract] [Full Text] [Related]
8. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
Sage JI; Mark MH
Clin Neuropharmacol; 1988 Apr; 11(2):174-9. PubMed ID: 3378226
[No Abstract] [Full Text] [Related]
9. New drugs for Parkinson's disease.
Hodges LC; Rapp CG
J Neurosci Nurs; 1990 Aug; 22(4):254-7. PubMed ID: 2144560
[TBL] [Abstract][Full Text] [Related]
10. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761
[No Abstract] [Full Text] [Related]
11. [Chronic inflammatory demyelinating polyradiculoneuropathy associated with treatment using intraduodenal infusion of levodopa-carbidopa].
Rivero-de-Aguilar A; Sesar A; Fernandez-Pajarin G; Ares-Pensado B; Castro A
Rev Neurol; 2019 Oct; 69(7):304-306. PubMed ID: 31559631
[TBL] [Abstract][Full Text] [Related]
12. Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.
Hutton JT; Dippel RL; Bianchine JR; Strahlendorf HK; Meyer PG
Clin Neuropharmacol; 1984; 7(2):135-9. PubMed ID: 6375861
[TBL] [Abstract][Full Text] [Related]
13. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease.
Nissenbaum H; Quinn NP; Brown RG; Toone B; Gotham AM; Marsden CD
Psychol Med; 1987 Nov; 17(4):899-904. PubMed ID: 3432464
[TBL] [Abstract][Full Text] [Related]
14. Sinemet CR in Parkinson's disease.
Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
[TBL] [Abstract][Full Text] [Related]
15. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
[No Abstract] [Full Text] [Related]
16. Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease.
Rosenthal SH; Fenton ML; Harnett DS
Gen Hosp Psychiatry; 1992 Jul; 14(4):285-6. PubMed ID: 1505751
[No Abstract] [Full Text] [Related]
17. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Pahwa R; Koller WC
Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
[No Abstract] [Full Text] [Related]
18. Treatment of Parkinson's disease.
Boyson SJ
Neurology; 1990 Apr; 40(4):725. PubMed ID: 2320258
[No Abstract] [Full Text] [Related]
19. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
Warren Olanow C; Torti M; Kieburtz K; Leinonen M; Vacca L; Grassini P; Heller A; Heller E; Stocchi F
Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
[TBL] [Abstract][Full Text] [Related]
20. Istradefylline (Nourianz) for Parkinson's disease.
Med Lett Drugs Ther; 2020 Feb; 62(1591):20-23. PubMed ID: 32022788
[No Abstract] [Full Text] [Related]
[Next] [New Search]
